|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM309323738 |
| 003 |
DE-627 |
| 005 |
20231225133648.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20200326-04
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1031.xml
|
| 035 |
|
|
|a (DE-627)NLM309323738
|
| 035 |
|
|
|a (NLM)32348539
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Rahimy, Ehsan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.04.2021
|
| 500 |
|
|
|a Date Revised 14.04.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2020, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: To evaluate impact of baseline systemic dipeptidyl peptidase-4 (DPP-4) inhibitor use in diabetic macular edema (DME)
|
| 520 |
|
|
|a PATIENTS AND METHODS: This was a post hoc exploratory analysis of previously completed randomized, controlled clinical trials (VISTA and VIVID) in patients with DME evaluating intravitreal aflibercept injection (IAI) every 4 weeks (2q4) or every 8 weeks (2q8) or macular laser photocoagulation
|
| 520 |
|
|
|a RESULTS: Overall, a small number of patients (12.2% [n = 35], 9.7% [n = 28], and 15.4% [n = 44]) in the laser control, 2q4, and 2q8 groups reported baseline DPP-4 inhibitor use. There were no differences in changes from baseline in best-corrected visual acuity, central subfield thickness, or rates of 2-or-greater-step improvement in Diabetic Retinopathy Severity Scale score based on DPP-4 inhibitor use within each treatment group
|
| 520 |
|
|
|a CONCLUSION: DPP-4 inhibitor use at baseline did not influence the magnitude of visual and anatomic benefit in patients with DME being treated with IAI or laser. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:226-234.]
|
| 650 |
|
4 |
|a Clinical Trial, Phase III
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Dipeptidyl-Peptidase IV Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 650 |
|
7 |
|a aflibercept
|2 NLM
|
| 650 |
|
7 |
|a 15C2VL427D
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Vascular Endothelial Growth Factor
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 700 |
1 |
|
|a Baker, Keith
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Thompson, Desmond
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saroj, Namrata
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a VIVID and VISTA Study Investigators
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 51(2020), 4 vom: 01. Apr., Seite 226-234
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
| 773 |
1 |
8 |
|g volume:51
|g year:2020
|g number:4
|g day:01
|g month:04
|g pages:226-234
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20200326-04
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 51
|j 2020
|e 4
|b 01
|c 04
|h 226-234
|